Searchable abstracts of presentations at key conferences in endocrinology

ea0098c38 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

Are there any clinical factors associated with PRRT-refractoriness in NET patients?

Gupta Garima , Yadav Rina , Yan Donglin , Anthony Lowell , Ramirez Robert , Chauhan Aman

Background: Peptide receptor radionuclide therapy (PRRT) with Lutetium-177 DOTATATE (LUTATHERA) is an effective treatment option for somatostatin receptor (SSTR) positive metastatic gastroenteropancreatic neuroendocrine tumors (NETs) and has also demonstrated antitumor activity in SSTR positive NETs from other primary sites. While the median progression free survival (mPFS) is around 29 months, there is a subset of patients who are refractory to PRRT and demonstrate progressio...